Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2026-02-01 @ 4:10 AM
Study NCT ID:
NCT05064358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-07
First Post:
2021-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
GlaxoSmithKline
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Myeloma | View |